← All Signals

🏥 FDA: AvKARE — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-03-16Date

Summary

AvKARE's recall of Amantadine due to failed dissolution specifications indicates a potential bioavailability issue, which could affect therapeutic efficacy. This may lead to temporary shortages and requires investigation into the manufacturing process.

Actionable: Evaluate supply chain for Amantadine HCl and monitor for competitor stock movements.

AI Confidence: 90%

Data Points

firmAvKARE
classificationClass II
statusOngoing
distributionNationwide in the USA.
productAmantadine HCl, Capsules, UPS, 100 mg, 50 Capsules (5 x 10) unit dose, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, www.avkare.com, NDC 50268

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now